Novartis India has officially announced the commercial launch of Pluvicto, marking the country’s premier regulatory-approved radioligand therapy (RLT) indicated for eligible patients presenting with prostate-specific membrane antigen (PSMA)-positive prostate cancer. This programmatic rollout introduces a significant milestone in precision oncology, expanding targeted molecular therapeutic options for patients battling metastatic prostate cancer.
The documented molecular targeted mechanisms, clinical toxicity mitigation profiles, and specialized institutional distribution networks feature:
-
Precision Molecular Targeting and Tissue Preservation Engineering:
-
Precision Oncology Framework: Pluvicto is structurally engineered to function as a theranostic modality, combining high-affinity biological targeting with therapeutic radiopharmaceuticals. The compound is designed to selectively bind to cancer cells overexpressing the specific PSMA protein, delivering localized radiation directly into the core of malignant plasma fields.
-
Collateral Damage Reduction: By binding precisely to cellular PSMA targets, the therapy restricts high-energy radiation exposure to the immediate microenvironment of the metastatic lesions. This mechanism minimizes ionizing destruction to surrounding healthy tissues and vital organs, addressing complex clinical and psychosocial therapeutic obstacles tied to late-stage oncological care.
-
-
Macro Access Strategies and Nuclear Medicine Distribution Frameworks:
-
Strategic Market Prioritization: Judith Love, Region Head of Asia Pacific, Middle East, and Africa at Novartis, reaffirmed that India remains a priority market for the multinational biopharmaceutical enterprise, driven by the expanding clinical momentum behind high-precision oncology and advanced oncological care pathways.
-
Controlled Specialized Distribution: Amitabh Dube, Country President and Managing Director of Novartis India, clarified that to maintain rigorous clinical quality control and safety, Pluvicto will be deployed exclusively through a curated network of select tier-one hospitals and accredited nuclear medicine centres nationwide. This partnership-led distribution model is designed to expand access to high-value radioligand pipelines while ensuring strict clinical compliance under specialized oncological supervision.
-